U. Hafeez, S. Parakh, H.K. Gan, A.M. Scott. Antibody-Drug Conjugates for Cancer Therapy. Molecules 25 (2020) 4764. https://doi.org/10.3390/molecules25204764

C. do Pazo, K. Nawaz, R.M. Webster. The oncology market for antibody-drug conjugates. Nat. Rev. Drug Discovery 20 (2021) 583-584. https://doi.org/10.1038/d41573-021-00054-2

J. Jiang, L. Dong, L. Wang, L. Wang, J. Zhang, F. Chen, X. Zhang, M. Huang, S. Li, W. Ma, Q. Xu, C. Huang, J. Fang, C. Wang. HER2-targeted antibody drug conjugates for ovarian cancer therapy. European Journal of Pharmaceutical Sciences 93 (2016) 274-286. https://doi.org/10.1016/j.ejps.2016.08.015

X. Sheng, X. Yan, L. Wang, Y. Shi, X. Yao, H. Luo, B. Shi, J. Liu, Z. He, G. Yu, J. Ying, W. Han, C. Hu, Y. Ling, Z. Chi, C. Cui, L. Si, J. Fang, A. Zhou, J. Guo. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research 27 (2021) 43-51. https://doi.org/10.1158/1078-0432.CCR-20-2488

Z. Peng, T. Liu, J. Wei, A. Wang, Y. He, L. Yang, X. Zhang, N. Fan, S. Luo, Z. Li, K. Gu, J. Lu, J. Xu, Q. Fan, R. Xu, L. Zhang, E. Li, Y. Sun, G. Yu, C. Bai, Y. Liu, J. Zeng, J. Ying, X. Liang, N. Xu, C. Gao, Y. Shu, D. Ma, G. Dai, S. Li, T. Deng, Y. Cui, J. Fang, Y. Ba, L. Shen. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Communications 41 (2021) 1173-1182. https://doi.org/10.1002/cac2.12214

Y. Xu, Y. Wang, J. Gong, X. Zhang, Z. Peng, X. Sheng, C. Mao, Q. Fan, Y. Bai, Y. Ba, D. Jiang, F. Yang, C. Qi, J. Li, X. Wang, J. Zhou, M. Lu, Y. Cao, J. Yuan, D. Liu, Z. Wang, J. Fang, L. Shen. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 24 (2021) 913-925. https://doi.org/10.1007/s10120-021-01168-7

J. Kalmuk, D. Rinder, C. Heltzel, A.C. Lockhart. An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. Expert Opinion on Drug Discovery 17 (2022) 427-436. https://doi.org/10.1080/17460441.2022.2050692

C. Li, C. Zhang, R. Deng, D. Leipold, D. Li, B. Latifi, Y. Gao, C. Zhang, Z. Li, D. Miles, S.C. Chen, D. Samineni, B. Wang, P. Agarwal, D. Lu, S. Prabhu, S. Girish, A.V. Kamath. Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates from Nonclinical Data. Clinical and Translational Science 12 (2019) 534-544. https://doi.org/10.1111/cts.12649

S.N. Liu, C. Li. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Cancer Chemotherapy and Pharmacology 87 (2021) 743-765. https://doi.org/10.1007/s00280-021-04250-0

`P.M. Drake, D. Rabuka. Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends. BioDrugs 31 (2017) 521-531. https://doi.org/10.1007/s40259-017-0254-1

A.V. Kamath, S. Iyer. Challenges and advances in the assessment of the disposition of antibody-drug conjugates. Biopharm. Drug Dispos. 37 (2016) 66-74. https://doi.org/10.1002/bdd.1957

J. Bolleddula, K. Brady, G. Bruin, A. Lee, J.A. Martin, M. Walles, K. Xu, T.Y. Yang, X. Zhu, H. Yu. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives. Drug Metabolism and Disposition 50 (2022) 837-845. https://doi.org/10.1124/dmd.121.000461

The U.S. Food and drug administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000PharmR.pdf

V. Yip, M.V. Lee, O.M. Saad, S. Ma, S.C. Khojasteh, B.Q. Shen. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody-Drug Conjugate in Sprague Dawley Rats. Journal of Clinical Medicine 10 (2021) 1323. https://doi.org/10.3390/jcm10061323

T.H. Han, A.K. Gopal, R. Ramchandren, A. Goy, R. Chen, J.V. Matous, M. Cooper, L.E. Grove, S.C. Alley, C.M. Lynch, O.A. O'Connor. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. The Journal of Clinical Pharmacology 53 (2013) 866-877. https://doi.org/10.1002/jcph.116